PMID- 23735945
OWN - NLM
STAT- MEDLINE
DCOM- 20140130
LR  - 20151119
IS  - 1875-8592 (Electronic)
IS  - 1574-0153 (Linking)
VI  - 12
IP  - 6
DP  - 2012-2013
TI  - Change in HER2 status during breast tumor progression.
PG  - 251-5
LID - 10.3233/CBM-130313 [doi]
AB  - The HER2 status of breast cancers is routinely assessed using the testing 
      algorithm standardized by the American Society of Clinical Oncology and the 
      College of American Pathologists, which includes immunohistochemical analysis of 
      HER2 protein expression and fluorescence in situ hybridization (FISH) analysis of 
      HER2 gene copy number. Studies have suggested that HER2 status may differ between 
      primary and metastatic tumors. Furthermore, studies have suggested that 
      trastuzumab may convert HER2 status from positive in a primary tumor to negative 
      in a metastatic site. Assessment of HER2 status is affected by aspects of the 
      pathologic analysis, including the method of tumor sampling, the method of 
      specimen fixation, whether immunohistochemical or FISH analysis is used. In this 
      review, we discuss the clinical significance of HER2 discordance in breast 
      cancer. Moreover, the importance of tumor sample handling in assessing 
      HER2-positivity.
FAU - Niikura, Naoki
AU  - Niikura N
AD  - Department of Breast and Endocrine Surgery, Tokai University School of Medicine, 
      Kanagawa, Japan.
FAU - Ueno, Naoto T
AU  - Ueno NT
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Netherlands
TA  - Cancer Biomark
JT  - Cancer biomarkers : section A of Disease markers
JID - 101256509
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/genetics/*metabolism
MH  - Breast Neoplasms/*enzymology/genetics/*pathology
MH  - Disease Progression
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Prognosis
MH  - Receptor, ErbB-2/genetics/*metabolism
EDAT- 2012/01/01 00:00
MHDA- 2014/01/31 06:00
CRDT- 2013/06/06 06:00
PHST- 2013/06/06 06:00 [entrez]
PHST- 2012/01/01 00:00 [pubmed]
PHST- 2014/01/31 06:00 [medline]
AID - JMH7N33T10073377 [pii]
AID - 10.3233/CBM-130313 [doi]
PST - ppublish
SO  - Cancer Biomark. 2012-2013;12(6):251-5. doi: 10.3233/CBM-130313.